Blueprint Medicines - BPMC Stock Forecast, Price & News

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of non-advanced SM and other mast cell disorders; and Fisogatinib, an orally available and potent inhibitor for the treatment of hepatocellular carcinoma. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered solid tumors, medullary thyroid carcinoma, and other solid tumors; BLU-701 and BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

Blueprint Medicines Stock Performance

Shares of NASDAQ:BPMC opened at $68.17 on Wednesday. The company has a market cap of $4.06 billion, a PE ratio of -5.74 and a beta of 0.94. The firm's 50 day moving average price is $54.72 and its 200-day moving average price is $61.20. Blueprint Medicines has a 52-week low of $43.46 and a 52-week high of $117.86.

Blueprint Medicines (NASDAQ:BPMC - Get Rating) last issued its earnings results on Tuesday, August 2nd. The biotechnology company reported ($2.68) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($2.23) by ($0.45). Blueprint Medicines had a negative net margin of 304.41% and a negative return on equity of 45.89%. The company had revenue of $36.55 million for the quarter, compared to analysts' expectations of $37.61 million. During the same period in the prior year, the firm posted ($1.86) earnings per share. The firm's revenue for the quarter was up 33.9% compared to the same quarter last year. On average, analysts forecast that Blueprint Medicines will post -9.18 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms recently weighed in on BPMC. SVB Leerink increased their target price on shares of Blueprint Medicines from $56.00 to $65.00 and gave the company a "market perform" rating in a research note on Wednesday, August 3rd. Jefferies Financial Group raised shares of Blueprint Medicines from a "hold" rating to a "buy" rating and cut their price target for the stock from $88.00 to $78.00 in a research report on Wednesday, June 1st. StockNews.com upgraded shares of Blueprint Medicines from a "sell" rating to a "hold" rating in a research note on Monday, May 9th. Robert W. Baird cut their price target on shares of Blueprint Medicines from $123.00 to $96.00 in a report on Wednesday, May 4th. Finally, Stifel Nicolaus cut their price target on Blueprint Medicines from $98.00 to $90.00 in a research note on Friday, July 1st. Two equities research analysts have rated the stock with a sell rating, four have issued a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $91.47.

Insider Activity at Blueprint Medicines

In other Blueprint Medicines news, insider Percy H. Carter sold 1,908 shares of Blueprint Medicines stock in a transaction dated Monday, June 6th. The shares were sold at an average price of $59.76, for a total transaction of $114,022.08. Following the transaction, the insider now directly owns 28,685 shares of the company's stock, valued at $1,714,215.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other Blueprint Medicines news, insider Percy H. Carter sold 1,908 shares of the business's stock in a transaction that occurred on Monday, June 6th. The shares were sold at an average price of $59.76, for a total transaction of $114,022.08. Following the completion of the transaction, the insider now owns 28,685 shares in the company, valued at approximately $1,714,215.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Christopher K. Murray sold 2,500 shares of the company's stock in a transaction on Thursday, August 4th. The shares were sold at an average price of $60.44, for a total transaction of $151,100.00. Following the completion of the sale, the senior vice president now owns 21,320 shares of the company's stock, valued at approximately $1,288,580.80. The disclosure for this sale can be found here. 3.42% of the stock is owned by company insiders.